Compare MXCT & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXCT | ACOG |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Canada |
| Employees | 91 | 57 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 110.4M |
| IPO Year | 2021 | N/A |
| Metric | MXCT | ACOG |
|---|---|---|
| Price | $1.24 | $6.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $5.50 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 932.0K | 30.3K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | $18.50 | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $4.50 |
| 52 Week High | $2.37 | $10.88 |
| Indicator | MXCT | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 57.26 |
| Support Level | $0.77 | $6.46 |
| Resistance Level | $1.30 | $6.92 |
| Average True Range (ATR) | 0.07 | 0.39 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 68.00 | 59.35 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.